Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Nov 1;102(9):1674–1681. doi: 10.1172/JCI3661

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.

V Patel 1, A M Senderowicz 1, D Pinto Jr 1, T Igishi 1, M Raffeld 1, L Quintanilla-Martinez 1, J F Ensley 1, E A Sausville 1, J S Gutkind 1
PMCID: PMC509115  PMID: 9802881

Abstract

Flavopiridol (HMR 1275) has been identified recently as a novel antineoplastic agent in the primary screen conducted by the Developmental Therapeutics Program, National Cancer Institute. Flavopiridol inhibits most cyclin-dependent kinases (cdks) and displays unique anticancer properties. Here, we investigated whether this compound was effective against head and neck squamous cell carcinomas (HNSCC). Exposure of HNSCC cells to flavopiridol diminished cdc2 and cdk2 activity and potently inhibited cell proliferation (IC50 43-83 nM), which was concomitant with the appearance of cells with a sub-G1 DNA content. Moreover, DNA fragmentation and TUNEL (terminal deoxynucleotidyl transferase-mediated nick end labeling) reaction confirmed that flavopiridol induces apoptosis in all cell lines, even on certain HNSCC cells that are insensitive to apoptosis to DNA-damaging agents (gamma-irradiation and bleomycin). A tumorigenic HNSCC cell line was used to assess the effect of flavopiridol in vivo. Treatment (5 mg/kg per day, intraperitoneally) for 5 d led to the appearance of apoptotic cells in the tumor xenografts and caused a 60-70% reduction in tumor size, which was sustained over a period of 10 wk. Flavopiridol treatment also resulted in a remarkable reduction of cyclin D1 expression in HNSCC cells and tumor xenografts. Our data indicate that flavopiridol exerts antitumor activity in HNSCC, and thus it can be considered a suitable candidate drug for testing in the treatment of refractory carcinomas of the head and neck.

Full Text

The Full Text of this article is available as a PDF (398.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arguello F., Alexander M., Sterry J. A., Tudor G., Smith E. M., Kalavar N. T., Greene J. F., Jr, Koss W., Morgan C. D., Stinson S. F. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. Blood. 1998 Apr 1;91(7):2482–2490. [PubMed] [Google Scholar]
  2. Bartkova J., Lukas J., Müller H., Strauss M., Gusterson B., Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res. 1995 Feb 15;55(4):949–956. [PubMed] [Google Scholar]
  3. Bates S. E., Fojo A. T., Weinstein J. N., Myers T. G., Alvarez M., Pauli K. D., Chabner B. A. Molecular targets in the National Cancer Institute drug screen. J Cancer Res Clin Oncol. 1995;121(9-10):495–500. doi: 10.1007/BF01197759. [DOI] [PubMed] [Google Scholar]
  4. Bible K. C., Kaufmann S. H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 1996 Nov 1;56(21):4856–4861. [PubMed] [Google Scholar]
  5. Cardinali M., Pietraszkiewicz H., Ensley J. F., Robbins K. C. Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int J Cancer. 1995 Mar 29;61(1):98–103. doi: 10.1002/ijc.2910610117. [DOI] [PubMed] [Google Scholar]
  6. Carlson B. A., Dubay M. M., Sausville E. A., Brizuela L., Worland P. J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996 Jul 1;56(13):2973–2978. [PubMed] [Google Scholar]
  7. Chen J. C., Shuler C. F., Zhang C. X., Schuller D. E., Milo G. E. Histopathologic comparison between human oral squamous cell carcinomas and their xenografts in nude mice. Oral Surg Oral Med Oral Pathol. 1991 Apr;71(4):457–463. doi: 10.1016/0030-4220(91)90430-k. [DOI] [PubMed] [Google Scholar]
  8. De Azevedo W. F., Jr, Mueller-Dieckmann H. J., Schulze-Gahmen U., Worland P. J., Sausville E., Kim S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2735–2740. doi: 10.1073/pnas.93.7.2735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Devesa S. S., Blot W. J., Stone B. J., Miller B. A., Tarone R. E., Fraumeni J. F., Jr Recent cancer trends in the United States. J Natl Cancer Inst. 1995 Feb 1;87(3):175–182. doi: 10.1093/jnci/87.3.175. [DOI] [PubMed] [Google Scholar]
  10. Drees M., Dengler W. A., Roth T., Labonte H., Mayo J., Malspeis L., Grever M., Sausville E. A., Fiebig H. H. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res. 1997 Feb;3(2):273–279. [PubMed] [Google Scholar]
  11. Elledge S. J. Cell cycle checkpoints: preventing an identity crisis. Science. 1996 Dec 6;274(5293):1664–1672. doi: 10.1126/science.274.5293.1664. [DOI] [PubMed] [Google Scholar]
  12. Gallo O., Chiarelli I., Bianchi S., Calzolari A., Simonetti L., Porfirio B. Loss of p53 gene mutation after irradiation is associated with increased aggressiveness in recurring head and neck cancer. Clin Cancer Res. 1996 Sep;2(9):1577–1582. [PubMed] [Google Scholar]
  13. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996;68:67–108. doi: 10.1016/s0065-230x(08)60352-8. [DOI] [PubMed] [Google Scholar]
  14. Jakus J., Yeudall W. A. Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells. Oncogene. 1996 Jun 6;12(11):2369–2376. [PubMed] [Google Scholar]
  15. Kaur G., Stetler-Stevenson M., Sebers S., Worland P., Sedlacek H., Myers C., Czech J., Naik R., Sausville E. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst. 1992 Nov 18;84(22):1736–1740. doi: 10.1093/jnci/84.22.1736. [DOI] [PubMed] [Google Scholar]
  16. Losiewicz M. D., Carlson B. A., Kaur G., Sausville E. A., Worland P. J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun. 1994 Jun 15;201(2):589–595. doi: 10.1006/bbrc.1994.1742. [DOI] [PubMed] [Google Scholar]
  17. Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993 Sep 24;74(6):957–967. doi: 10.1016/0092-8674(93)90719-7. [DOI] [PubMed] [Google Scholar]
  18. Meijer L., Kim S. H. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol. 1997;283:113–128. doi: 10.1016/s0076-6879(97)83011-x. [DOI] [PubMed] [Google Scholar]
  19. Michalides R. J., van Veelen N. M., Kristel P. M., Hart A. A., Loftus B. M., Hilgers F. J., Balm A. J. Overexpression of cyclin D1 indicates a poor prognosis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1997 May;123(5):497–502. doi: 10.1001/archotol.1997.01900050045005. [DOI] [PubMed] [Google Scholar]
  20. Michalides R., van Veelen N., Hart A., Loftus B., Wientjens E., Balm A. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res. 1995 Mar 1;55(5):975–978. [PubMed] [Google Scholar]
  21. Ornstein S. M., Jenkins R. G., Edsall R. L. Computerized patient record systems: a survey of 28 vendors. Fam Pract Manag. 1997 Nov-Dec;4(10):45-8, 51-9. [PubMed] [Google Scholar]
  22. Parker B. W., Kaur G., Nieves-Neira W., Taimi M., Kohlhagen G., Shimizu T., Losiewicz M. D., Pommier Y., Sausville E. A., Senderowicz A. M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood. 1998 Jan 15;91(2):458–465. [PubMed] [Google Scholar]
  23. Patel V., Jakus J., Harris C. M., Ensley J. F., Robbins K. C., Yeudall W. A. Altered expression and activity of G1/S cyclins and cyclin-dependent kinases characterize squamous cell carcinomas of the head and neck. Int J Cancer. 1997 Nov 14;73(4):551–555. doi: 10.1002/(sici)1097-0215(19971114)73:4<551::aid-ijc16>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  24. Rosenberg D., Cretin S. Use of meta-analysis to evaluate tolonium chloride in oral cancer screening. Oral Surg Oral Med Oral Pathol. 1989 May;67(5):621–627. doi: 10.1016/0030-4220(89)90286-7. [DOI] [PubMed] [Google Scholar]
  25. Sellins K. S., Cohen J. J. Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol. 1987 Nov 15;139(10):3199–3206. [PubMed] [Google Scholar]
  26. Senderowicz A. M., Headlee D., Stinson S. F., Lush R. M., Kalil N., Villalba L., Hill K., Steinberg S. M., Figg W. D., Tompkins A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998 Sep;16(9):2986–2999. doi: 10.1200/JCO.1998.16.9.2986. [DOI] [PubMed] [Google Scholar]
  27. Sherwood S. W., Schimke R. T. Cell cycle analysis of apoptosis using flow cytometry. Methods Cell Biol. 1995;46:77–97. doi: 10.1016/s0091-679x(08)61925-1. [DOI] [PubMed] [Google Scholar]
  28. Silverman S. Oral cancer. Semin Dermatol. 1994 Jun;13(2):132–137. [PubMed] [Google Scholar]
  29. Siodlak M. Z., Stell P. M., Wilson J. A., Green J. A., Allison R. S., Adler D., Squadrelli-Saraceno M. Alternating cisplatinum and VAC ineffective in end stage squamous cell carcinoma of the head and neck. J Laryngol Otol. 1990 Aug;104(8):631–633. doi: 10.1017/s0022215100113441. [DOI] [PubMed] [Google Scholar]
  30. Stell P. M., Rawson N. S. Adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1990 May;61(5):779–787. doi: 10.1038/bjc.1990.175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Weinstein J. N., Myers T. G., O'Connor P. M., Friend S. H., Fornace A. J., Jr, Kohn K. W., Fojo T., Bates S. E., Rubinstein L. V., Anderson N. L. An information-intensive approach to the molecular pharmacology of cancer. Science. 1997 Jan 17;275(5298):343–349. doi: 10.1126/science.275.5298.343. [DOI] [PubMed] [Google Scholar]
  32. Worland P. J., Kaur G., Stetler-Stevenson M., Sebers S., Sartor O., Sausville E. A. Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem Pharmacol. 1993 Nov 17;46(10):1831–1840. doi: 10.1016/0006-2952(93)90590-s. [DOI] [PubMed] [Google Scholar]
  33. Yeudall W. A., Crawford R. Y., Ensley J. F., Robbins K. C. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis. 1994 Dec;15(12):2683–2686. doi: 10.1093/carcin/15.12.2683. [DOI] [PubMed] [Google Scholar]
  34. Yeudall W. A., Jakus J., Ensley J. F., Robbins K. C. Functional characterization of p53 molecules expressed in human squamous cell carcinomas of the head and neck. Mol Carcinog. 1997 Feb;18(2):89–96. doi: 10.1002/(sici)1098-2744(199702)18:2<89::aid-mc4>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES